ES2081384T3 - Preparado farmaceutico que contiene complejos de polielectrolitos en forma de microparticulas y por lo menos una sustancia activa. - Google Patents

Preparado farmaceutico que contiene complejos de polielectrolitos en forma de microparticulas y por lo menos una sustancia activa.

Info

Publication number
ES2081384T3
ES2081384T3 ES91106495T ES91106495T ES2081384T3 ES 2081384 T3 ES2081384 T3 ES 2081384T3 ES 91106495 T ES91106495 T ES 91106495T ES 91106495 T ES91106495 T ES 91106495T ES 2081384 T3 ES2081384 T3 ES 2081384T3
Authority
ES
Spain
Prior art keywords
active substance
microparticles
pharmaceutical preparation
preparation containing
polyelectrolyte complexes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91106495T
Other languages
English (en)
Inventor
Volker Dr Krone
Michael Dr Magerstadt
Axel Dr Walch
Albrecht Dr Groner
Dieter Dr Hoffmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE4013110A external-priority patent/DE4013110A1/de
Priority claimed from DE4035187A external-priority patent/DE4035187A1/de
Application filed by Hoechst AG filed Critical Hoechst AG
Application granted granted Critical
Publication of ES2081384T3 publication Critical patent/ES2081384T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B23/00—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes
    • G09B23/28—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine
    • G09B23/286—Models for scientific, medical, or mathematical purposes, e.g. full-sized devices for demonstration purposes for medicine for scanning or photography techniques, e.g. X-rays, ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasonic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasonic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Algebra (AREA)
  • Business, Economics & Management (AREA)
  • Organic Chemistry (AREA)
  • Computational Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mathematical Analysis (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Physics (AREA)
  • Pure & Applied Mathematics (AREA)
  • Medical Informatics (AREA)
  • Educational Administration (AREA)
  • Educational Technology (AREA)
  • Theoretical Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Acoustics & Sound (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA INVENCION SE REFIERE A UNA PREPARACION FARMACOLOGICA: QUE CONTIENE UN COMPLEJO DE POLIELECTROILO FORMADO POR UN ACIDO POLIOICO CON UN TAMAÑO DE GRANO MENOR DE 15 MM Y UNA MATERIA ACTIVA ELEGIDA ENTRE PEPTIDO ACTIVO, PROTEINA, ENZIMA, CITOSTATO, ANTIINFLAMATORIO, ANTIBIOTICA Y VACUNAS: GARANTIZA LA APLICACION DE LA MATERIA ACTIVA EN UNA FORMA CONOCIDA E INFLUYE POSITIVAMENTE EN LA DISTRIBUCION Y DISPONIBILIDAD BIOLOGICA Y EN LA RESORCION DE LOS MEDICAMENTOS.
ES91106495T 1990-04-25 1991-04-23 Preparado farmaceutico que contiene complejos de polielectrolitos en forma de microparticulas y por lo menos una sustancia activa. Expired - Lifetime ES2081384T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4013110A DE4013110A1 (de) 1990-04-25 1990-04-25 Pharmakologische zubereitung, enthaltend polyelektrolytkomplexe in mikropartikulaerer form und mindestens einen wirkstoff
DE4035187A DE4035187A1 (de) 1990-11-06 1990-11-06 Pharmakologische zubereitung, enthaltend polyelektrolytkomplexe in mikropartikulaerer form und mindestens einen wirkstoff

Publications (1)

Publication Number Publication Date
ES2081384T3 true ES2081384T3 (es) 1996-03-01

Family

ID=25892501

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91106495T Expired - Lifetime ES2081384T3 (es) 1990-04-25 1991-04-23 Preparado farmaceutico que contiene complejos de polielectrolitos en forma de microparticulas y por lo menos una sustancia activa.

Country Status (9)

Country Link
US (1) US5700459A (es)
EP (1) EP0454044B1 (es)
JP (1) JP3168215B2 (es)
AT (1) ATE131042T1 (es)
CA (1) CA2041093C (es)
DE (1) DE59107006D1 (es)
DK (1) DK0454044T3 (es)
ES (1) ES2081384T3 (es)
IE (1) IE70747B1 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9205298A (es) 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
HU218018B (hu) * 1991-09-17 2000-05-28 Sonus Pharmaceuticals Inc. Gázos ultrahang-kontrasztanyag és eljárás ultrahang kontrasztanyaghoz megfelelő gázok kiválasztására
US5409688A (en) * 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
DE69207589T2 (de) * 1992-06-01 1996-05-23 Basf Ag Anwendung von Dispersionen von magneto-ionischen Partikeln in MRI-Kontrast-Mitteln
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Phase shift colloids as ultrasound contrast agents
EP0680341B1 (en) * 1993-01-25 2001-05-09 Sonus Pharmaceuticals, Inc. Phase shift colloids as ultrasound contrast agents
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
US5981719A (en) 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
AUPM572294A0 (en) * 1994-05-18 1994-06-09 Vaccine Technologies Pty. Ltd. Delivery vehicle for bioactive molecule
EP0773975A4 (en) * 1994-08-04 1998-06-10 Gordon George Wallace CONDUCTIVE ELECTROACTIVE BIOMATERIALS
US6165988A (en) * 1995-02-10 2000-12-26 Christian Noe Medicament in particulate form
GB9522351D0 (en) * 1995-11-01 1996-01-03 Medeva Holdings Bv Vaccine compositions
DE19611769A1 (de) * 1996-03-14 1997-09-18 Schering Ag Mikropartikel, Verfahren zu deren Herstellung, sowie deren Verwendung in der Ultraschall Diagnostik
CN1135265C (zh) * 1996-04-12 2004-01-21 诺沃奇梅兹有限公司 含酶颗粒及其生产方法
DE69727244T2 (de) * 1996-10-03 2004-11-25 Hermes Biosciences Inc., San Francisco Hydrophile Mikroteilchen und Verfahren zu deren Herstellung
AU4941297A (en) * 1996-11-15 1998-06-10 Dumex-Alpharma A/S A method for promoting tissue repair
DE19712718C2 (de) * 1997-03-26 1999-09-23 Asta Medica Ag Immobilisierte und aktivitätsstabilisierte Komplexe von LHRH-Antagonisten und Verfahren zu deren Herstellung
US20030170313A1 (en) * 1997-10-09 2003-09-11 Ales Prokop Micro-particulate and nano-particulate polymeric delivery system
AU9799198A (en) * 1997-10-09 1999-05-03 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
US6726934B1 (en) * 1997-10-09 2004-04-27 Vanderbilt University Micro-particulate and nano-particulate polymeric delivery system
DE19810965A1 (de) * 1998-03-13 1999-09-16 Aventis Res & Tech Gmbh & Co Nanopartikel, Verfahren zu ihrer Herstellung und ihre Verwendung
JP2002536317A (ja) * 1999-02-03 2002-10-29 パウダージェクト リサーチ リミテッド ヒドロゲル粒子処方物
US6645525B1 (en) 1999-06-23 2003-11-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
DE19940795A1 (de) * 1999-08-27 2001-03-01 Lohmann Therapie Syst Lts Schnellzerfallende Pellets auf der Basis von Chitosan
US20020051821A1 (en) * 2000-09-08 2002-05-02 Sung-Yun Kwon Aliginate particle formulation
US8394813B2 (en) 2000-11-14 2013-03-12 Shire Llc Active agent delivery systems and methods for protecting and administering active agents
DE10132669B4 (de) * 2001-07-05 2008-08-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Pharmakologische Zubereitung aus einem nanopartikulären mesomorphen Polyelektrolyt-Lipid-Komplex und mindestens einem Wirkstoff
US20050191361A1 (en) * 2001-08-03 2005-09-01 Powederject Research Ltd. Hydrogel particle formation
US7169752B2 (en) 2003-09-30 2007-01-30 New River Pharmaceuticals Inc. Compounds and compositions for prevention of overdose of oxycodone
WO2003057716A2 (en) * 2002-01-08 2003-07-17 New River Pharmaceuticals, Inc. Dendritic encapsulation of active agents
US8088388B2 (en) * 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
FR2843302B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
FR2843301B1 (fr) * 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
EP2460530A3 (en) * 2002-12-31 2012-08-29 Althea Technologies, Inc. Human growth hormone crystals and methods for preparing them
NZ554885A (en) * 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
US8133881B2 (en) 2003-01-13 2012-03-13 Shire Llc Carbohydrate conjugates to prevent abuse of controlled substances
JP4684991B2 (ja) * 2003-01-31 2011-05-18 ボストン サイエンティフィック リミテッド 薬物添加ナノカプセルを用いる局所的薬物デリバリー
US7364585B2 (en) * 2003-08-11 2008-04-29 Boston Scientific Scimed, Inc. Medical devices comprising drug-loaded capsules for localized drug delivery
DE10350248A1 (de) * 2003-10-28 2005-06-16 Magnamedics Gmbh Thermosensitive, biokompatible Polymerträger mit veränderbarer physikalischer Struktur für die Therapie, Diagnostik und Analytik
US8012457B2 (en) 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
US20090036553A1 (en) * 2004-07-08 2009-02-05 Shire Llc Dendritic encapsulation of active agents
US20060110429A1 (en) * 2004-11-24 2006-05-25 Therakine Corporation Implant for intraocular drug delivery
CN101128187A (zh) * 2005-02-09 2008-02-20 达沃尔泰拉公司 活性剂的结肠递送
EP1872793B1 (en) 2005-04-20 2012-10-10 Mitsuru Akashi Polyamino acid for use as adjuvant
ES2277743B2 (es) 2005-06-02 2008-12-16 Universidade De Santiago De Compostela Nanoparticulas que comprenden quitosano y ciclodextrina.
EP1760467A1 (en) * 2005-09-02 2007-03-07 Schering AG Optically fluorescent nanoparticles
US20090023629A1 (en) * 2005-12-23 2009-01-22 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
US8273376B2 (en) 2006-11-17 2012-09-25 Da Volterra Colonic delivery of metallo-dependent enzymes
US20080124279A1 (en) * 2006-11-17 2008-05-29 Antoine Andremont Colonic delivery using Zn/pectin beads with a Eudragit coating
EP2135601A1 (en) * 2008-06-20 2009-12-23 Capsulution Nanoscience AG Stabilization of amorphous drugs using sponge-like carrier matrices
WO2010087781A1 (en) * 2009-01-28 2010-08-05 Agency For Science, Technology And Research Polyelectrolyte complexes with bound peptides
JP5522486B2 (ja) * 2009-03-27 2014-06-18 国立大学法人 鹿児島大学 疎水化ポリアミノ酸からなるポリイオンコンプレックスとその用途
CN102858367B (zh) 2010-02-26 2014-12-17 国立大学法人长崎大学 抗原或药物递送复合物
GB201014121D0 (en) * 2010-08-24 2010-10-06 Univ Gent Particulate biologic drug delivery system
FR2967580A1 (fr) * 2010-11-18 2012-05-25 Centre Nat Rech Scient Materiau comprenant un polysaccharide acide et un biopolymere cationique
TW201249843A (en) * 2011-06-14 2012-12-16 Univ Kaohsiung Medical Processes for preparing amine salts of KMUP-3 and use thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5227M (es) * 1966-03-18 1967-08-14
US4409331A (en) * 1979-03-28 1983-10-11 Damon Corporation Preparation of substances with encapsulated cells
US4495288A (en) * 1981-03-13 1985-01-22 Damon Biotech, Inc. Method of culturing anchorage dependent cells
EP0127989A3 (en) * 1983-06-01 1986-03-26 Connaught Laboratories Limited Microencapsulation of living tissue and cells
CA1196862A (en) * 1983-06-01 1985-11-19 Connaught Laboratories Limited Microencapsulation of living tissue and cells
US4663286A (en) * 1984-02-13 1987-05-05 Damon Biotech, Inc. Encapsulation of materials
DE3575375D1 (de) * 1984-02-15 1990-02-22 Massachusetts Inst Technology Verfahren zur verkapselung und systeme mit verkapseltem aktivmaterial.
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8500121D0 (en) * 1985-01-03 1985-02-13 Connaught Lab Microencapsulation of living cells
DE3788301D1 (de) * 1986-05-15 1994-01-13 Hoechst Ag Biologisch abbaubare Polymere für Depotzubereitungen mit kontrollierter Wirkstoffabgabe.
US4741872A (en) * 1986-05-16 1988-05-03 The University Of Kentucky Research Foundation Preparation of biodegradable microspheres useful as carriers for macromolecules
US5354844A (en) * 1989-03-16 1994-10-11 Boehringer Ingelheim International Gmbh Protein-polycation conjugates
CA2014244A1 (en) * 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Stabilized composition of anthracyclines

Also Published As

Publication number Publication date
CA2041093A1 (en) 1991-10-26
EP0454044B1 (de) 1995-12-06
ATE131042T1 (de) 1995-12-15
DE59107006D1 (de) 1996-01-18
JPH04225915A (ja) 1992-08-14
CA2041093C (en) 2004-08-03
US5700459A (en) 1997-12-23
JP3168215B2 (ja) 2001-05-21
EP0454044A3 (en) 1993-01-13
DK0454044T3 (da) 1996-04-22
IE911369A1 (en) 1991-11-06
IE70747B1 (en) 1996-12-30
EP0454044A2 (de) 1991-10-30

Similar Documents

Publication Publication Date Title
ES2081384T3 (es) Preparado farmaceutico que contiene complejos de polielectrolitos en forma de microparticulas y por lo menos una sustancia activa.
DE3868037D1 (de) Pharmazeutische zusammensetzung mit verzoegerter wirkstoffabgabe.
FI863074A7 (fi) Farmaseuttisesti aktiivisten aineiden rakeinen, hidasluovutteinen muoto.
DE3676235D1 (de) Arzneizubereitung mit verzoegerter wirkstoffabgabe.
NO851170L (no) Lagringsstabile, hurtignedbrytende farmasoeytiske virksomme stoff-presslegemer
KR890701076A (ko) 온도-조절된 활성약제 디스펜서
DK457288D0 (da) Kapsel til farmaceutisk virksomme stoffer
DE69000881D1 (de) 2-propylvaleriansaeure enthaltende arzneizubereitung mit verzoegerter wirkstofffreigabe.
NL194239B (nl) Dialkoxyfosfinolmethylbenzamideverbindingen en farmaceutische preparaten, die deze bevatten.
EP0230575A3 (de) Arzneimittel mit Antitumorwirkung das Hexadecylphosphocholin enthält
DK175487D0 (da) Farmaceutisk aktive 2-thiomethyl-substitueret-1,4-dihydro-pyridiner
EE05620B1 (et) Omeprasooli mikrograanulid, nende valmistamismeetod ja farmatseutilised preparaadid
DE69739165D1 (de) Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
ES2019398B3 (es) Nueva composicion para alimentacion de rumiantes, que contiene una sustancia biologicamente activa y su preparacion.
ES2130420T3 (es) Preparado transdermico de sustancia activa.
DE69830095D1 (de) Pharmazeutischer, kosmetischer oder dermo-pharmazeutischer Patch zur Verabreichung mehrerer verschiedenartiger Aktivstoffe
FI932553A0 (fi) Nya farmaceutiska formulationer innehaollande ett farmakologiskt aktivtjoniserbart aemne samt process foer framstaellning daerav
DE3669104D1 (de) Pharmazeutische praeparate, die ascorbinsaeurederivate enthalten.
NL192561B (nl) Oogontstekings-werende middelen. Oftalmische preparaten die bepaalde fenylazijnzuurverbindingen bevatten.
ES2137241T3 (es) Formulaciones de acido metanodifosfonico con intercambiadores de iones.
DE3769707D1 (de) Therapeutisches system mit geregelter wirkstoffabgabe.
DE3685869D1 (de) Formulierung mit verzoegerter wirkstoffabgabe, die ein hydrophobes polymersystem enthaelt.
ES2077559T3 (es) Estabilizacion de proteinas terapeuticamente activas en preparados farmaceuticos.
IT8323059A0 (it) Tripeptide e tetrapeptide alchilamidi biologicamente attive, processi per la loro preparazione e composizioni farmaceutiche che le contengono.
AU566240B2 (en) Dosage device for dosing microcapsules containing pharmacologically active substances

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 454044

Country of ref document: ES